Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Chong Zuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6117-6438; OpenAlex author ID A5042764293. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 10

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. First author DOI 10.1038/s41590-023-01579-x↗
  4. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  5. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  6. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1039226↗
  7. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗
  8. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
  9. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Co-author DOI 10.1126/scitranslmed.aau9240↗
  10. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Co-author DOI 10.1016/j.immuni.2017.07.014↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 7 shared papers, 2017–2023 · strength 0.76
  2. William G. Hawkins · 6 shared papers, 2017–2023 · strength 0.62
  3. Ryan C Fields · 6 shared papers, 2017–2023 · strength 0.62
  4. Graham D. Hogg · 5 shared papers, 2019–2023 · strength 0.56
  5. Harshabad Singh · 2 shared papers, 2026 · strength 0.38
  6. Michael Lawrence Dougan · 2 shared papers, 2026 · strength 0.38
  7. Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
  8. George Molina · 2 shared papers, 2026 · strength 0.38
  9. Thomas E. Clancy · 2 shared papers, 2026 · strength 0.38
  10. Douglas Adam Rubinson · 2 shared papers, 2026 · strength 0.38
  11. Sarah Slater · 2 shared papers, 2026 · strength 0.38
  12. Brian Matthew Wolpin · 2 shared papers, 2026 · strength 0.38
  13. Brandon M. Huffman · 2 shared papers, 2026 · strength 0.38
  14. Joseph Douglas Mancias · 2 shared papers, 2026 · strength 0.38
  15. Jonathan Andrew Nowak · 2 shared papers, 2026 · strength 0.38
  16. Kimberly J. Perez · 2 shared papers, 2026 · strength 0.38
  17. Stephanie K. Dougan · 2 shared papers, 2026 · strength 0.38
  18. James M. Cleary · 2 shared papers, 2026 · strength 0.38
  19. John M. Baer · 3 shared papers, 2020–2023 · strength 0.37
  20. Li Ding · 2 shared papers, 2023 · strength 0.28
  21. Hui Chin Peng · 2 shared papers, 2021–2022 · strength 0.26
  22. William E. Gillanders · 2 shared papers, 2021–2022 · strength 0.26
  23. C. Alston James · 2 shared papers, 2021–2023 · strength 0.25
  24. Varintra E. Lander · 2 shared papers, 2020–2023 · strength 0.23
  25. Yu Zhu · 2 shared papers, 2017–2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.